-Reuters
‘Running Out Of Money’: AI Firms That Took Bold Bets May Need To Sell
Firms with limited cash balances are burning through their funds to keep afloat.
Related Posts
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $45
Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $40 to $45.
Transphorm Announces Two 4-Lead TO-247 Devices, Expanding Product Portfolio For High Power Server, Renewable, Industrial Power Conversion
New FETs Serve as an Original Design Option or Drop-In Replacement for SiCTransphorm, Inc. (NASDAQ:TGAN), the global leader in robust GaN power semiconductors, today announced availability of two new SuperGaN®
Spectaire Announces Manufacturing Financing Agreement To Enable Mass Production
Spectaire Holdings Inc. (NASDAQ:SPEC) ("Spectaire" or the "Company"), a leader in air quality monitoring and emissions reduction technology, today announced further details of its balance sheet-light business model in